Here are four takeaways:
1. KPI will develop topical biologic Kv1.3 inhibitors that target the immune cells which cause these autoimmune diseases.
2. KPI is also currently conducting research in lupus and chronic pain.
3. The two research programs, KPI-150 and KPI-190 are already underway.
4. KPI Therapeutics is a clinical-stage biotechnology company which develops first-in-class therapies for unmet medical needs in autoimmunity and chronic pain.
More articles on healthcare:
Nueterra divides into 2 companies: 4 highlights
15 statistics on physician investment mistakes
7 things to ASC leaders to know for Monday — Feb. 8, 2016
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
